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Abstract
AIM: To investigate perfusion change in contrast-
enhanced ultrasonography (CEUS) to evaluate liver 
fibrosis based on biliary obstruction using an animal 
model. 
METHODS: New Zealand white rabbits (3-4 kg) 
underwent bile duct ligation to form a biliary obstruction 
model. We performed liver CEUS and laboratory tests 
on the day before the operation (day 0) and every 7 
postoperative days until the rabbits were sacrificed. 
After CEUS, signal intensity of liver parenchyma 
with a time-intensity curve was analyzed. Perfusion 
parameters were automatically calculated from region-
of-interests, including peak signal intensity, mean 
transit time, area under the curve and time to peak. 
Histological grades of liver fibrosis were assessed 
according to the Metavir score system immediately after 
sacrifice. Generalized estimating equations were used 
to analyze the association between liver fibrosis grades 
and perfusion parameters for statistical analysis. The 
perfusion parameters were measured on the last day 
and the difference between day 0 and the last day were 
evaluated.
RESULTS: From the nine rabbits, histological grades 
of liver fibrosis were grade 1 in one rabbit, grade 2 and 
3 in three rabbits each, and grade 4 in two rabbits. 
Among the four CEUS parameters, only the peak signal 
intensity measured on the last day demonstrated a 
significant association with liver fibrosis grades (OR = 
1.392, 95%CI: 1.114-1.741, P  = 0.004). The difference 
in peak signal intensity between day 0 and the last day 
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v21.i9.2614
2614 March 7, 2015|Volume 21|Issue 9|WJG|www.wjgnet.com
World J Gastroenterol  2015 March 7; 21(9): 2614-2621
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.
ORIGINAL ARTICLE
Contrast-enhanced ultrasonography for the evaluation of 
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also demonstrated an association with liver fibrosis 
(OR = 1.191, 95%CI: 0.999-1.419, P  = 0.051). The 
other parameters tested, including mean transit time, 
area under the curve, and time to peak, showed no 
significant correlation with liver fibrosis grades.
CONCLUSION: This animal study demonstrates that 
CEUS can be used to evaluate liver fibrosis from biliary 
obstruction using peak signal intensity as a parameter. 
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Liver cirrhosis; Animals; Bile ducts; Ligation; Rabbits
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Core tip: Contrast-enhanced ultrasonography (CEUS) 
was proposed for the evaluation of liver fibrosis. 
However, no previous studies have evaluated the 
utility of CEUS for liver fibrosis caused by biliary 
obstruction, which can be the major cause of liver 
fibrosis in children. Therefore, we investigated the 
feasibility of CEUS to evaluate liver fibrosis from biliary 
obstruction by quantitatively assessing perfusion 
changes in an animal model with bile duct ligation. We 
also demonstrated that the parameter of peak signal 
intensity from CEUS could be useful to evaluate liver 
fibrosis from biliary obstruction.
Shin HJ, Chang EY, Lee HS, Hong JH, Park G, Kim HG, 
Kim MJ, Lee MJ. Contrast-enhanced ultrasonography for the 
evaluation of liver fibrosis after biliary obstruction. World J 
Gastroenterol 2015; 21(9): 2614-2621  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i9/2614.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i9.2614
INTRODUCTION
Contrast-enhanced ultrasonography (CEUS) is an 
examination based on blood pool tracer visualization 
using ultrasound contrast agents during real-time 
ultrasonography (US) imaging. CEUS assessment 
can be made by canceling and separating of linear 
ultrasound signals from tissues and by utilizing 
non-linear signals from microbubbles[1]. Although 
visualization of the microvasculature is limited in 
conventional US, computed tomography (CT) and 
magnetic resonance imaging (MRI), it becomes 
possible through CEUS. Moreover, CEUS can 
quantitatively measure blood flow and perfusion using 
contrast kinetic curves obtained from quantification 
software[2]. This method had high diagnostic 
performance and clinical utility for detecting and 
characterizing focal liver lesions[3,4]. Moreover, the 
European Federation of Societies for Ultrasound in 
Medicine and Biology documented guidelines for 
utilizing CEUS, not only for liver assessment, but also 
for other organs, especially for diagnosing focal lesions 
and monitoring treatment response[1,5].
Previous studies also demonstrated the role 
of CEUS for evaluating liver fibrosis because local 
and hemodynamic changes accompanied fibrotic 
liver changes[6]. The severity of cirrhosis can be 
evaluated with enhanced signal intensity of the liver 
parenchyma on CEUS[7,8]. However, the utility of CEUS 
in liver fibrosis from biliary obstruction has not been 
evaluated. 
Liver fibrosis occurs in adults, but can also occur 
in children; however, the causes of liver fibrosis are 
different in children compared with adults. The major 
indication for liver transplantation in children is biliary 
atresia, which causes biliary cirrhosis[9], despite the 
fact that the pathophysiology of biliary atresia is not 
well known. Hartley et al[10] commented that biliary 
atresia might be a final common phenotype for several 
pathogenic processes. Additionally, liver fibrosis 
progresses rapidly before and even after performing a 
hepatoportoenterostomy for bile drainage[11]. Therefore, 
early and accurate evaluation of liver fibrosis in pediatric 
patients with biliary atresia is important. Liver fibrosis 
evaluation with CEUS can be particularly useful in 
pediatric patients because of the absence of radiation 
exposure and because it is easy to perform without 
sedation. However, to our knowledge, no previous 
studies have evaluated the utility of CEUS for liver 
fibrosis caused by biliary obstruction. 
Therefore, the aim of this study was to investigate 
the feasibility of CEUS to evaluate liver fibrosis 
from biliary obstruction by quantitatively assessing 
perfusion change using an animal model. We per-
formed serial follow-up before and after operation 
of biliary obstruction and examined US features and 
changes in perfusion parameter patterns from CEUS 
that correlated with liver fibrosis induced by biliary 
obstruction.
MATERIALS AND METHODS
Experimental protocol
This study protocol was approved by our institutional 
animal experimental committee and performed 
according to local animal care guidelines. Nine male 
New Zealand white rabbits that weighed 3-4 kg were 
included. Under general anesthesia, the common 
bile ducts were ligated with suture material by one 
pediatric surgeon (E.Y.C.). The rabbits were maintained 
on a standard diet after the operation. 
Laboratory tests were also performed before 
and after the operation, including measurement 
of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and total bilirubin levels. 
The upper normal limits of the laboratory tests were 
36 IU/L for AST, 72 IU/L for ALT, and 1.0 mmol/L for 
total bilirubin. Preoperative tests were performed just 
before starting the operation. Postoperative tests were 
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performed at the postoperative day 3, day 7, every 7 d, 
and the last was performed prior to sacrifice. The time 
of sacrifice was agreed upon by the veterinarian (G.P.) 
and radiologists according to the rabbits’ condition. 
Imaging study including CEUS
Abdominal US was performed while the rabbits were 
under sedation on the day before the operation (day 0) 
and every 7 postoperative days until the rabbits were 
sacrificed. Additional examination was performed just 
before the sacrifice, if possible. 
The imaging study, including CEUS, was performed 
using an ultrasound unit (iU22, Philips Medical 
Systems, Best, The Netherlands) equipped with a 
L12-5 linear transducer (5-12 MHz). All US evaluations 
were performed by one of two board-certified 
radiologists (M.J.L. and H.J.S.). Before the CEUS study, 
intrahepatic bile duct dilatation from successful bile 
duct ligation was confirmed on US. For CEUS imaging, 
we captured the images of relatively homogeneous 
liver parenchyma without shadowing from the bowel or 
ribs. Lipid-based ultrasound contrast agent (SonoVue, 
Bracco, Milan, Italy) dissolved with a 5-mL physiologic 
saline solution was used. Then 0.4 mL of mixed 
contrast agent was administered as a bolus into the 
ear vein of the rabbit, followed by a 2-mL saline flush. 
The images were recorded continuously for three 
minutes from the time of contrast injection, and these 
procedures were repeated twice. The time interval 
between the two CEUS examinations was more than 
five minutes. 
Image analysis
The cine clips were downloaded in the DICOM format 
for offline processing (QLAB software, Philips Medical 
Systems, Best, The Netherlands) with a bolus kinetic 
model for acquiring the perfusion parameters from the 
CEUS examinations. We drew a region-of-interest (ROI) 
in the liver parenchyma and avoided hepatic vessels 
or dilated bile ducts. The software automatically 
presented absolute time to echo mean (dB) curve with 
a curve fitting method (Figure 1). It also automatically 
calculated perfusion parameters of the ROI, including 
peak signal intensity (PSI, dB), mean transit time 
(MTT, s), area under the curve (AUC, dB s) and time 
to peak (TTP, s). The values were obtained three times 
from the two examinations by the same radiologists 
with a blind-check of parameters in the same rabbits. 
From the three values, mean values were obtained as 
representative values.
Pathologic evaluation
Immediately after sacrifice, liver specimens were fixed 
in 10% formalin, embedded in paraffin, cut into 3-mm-
thick sections, and stained with Masson’s trichrome. 
Histological grades of liver fibrosis were assessed 
according to the Metavir score system[12,13]. The 
fibrosis score was evaluated from this semiquantitative 
classification system as follows: 0 = no fibrosis, 1 = 
portal fibrosis without septa, 2 = few septal fibrosis, 3 
= numerous septal fibrosis without cirrhosis, and 4 = 
cirrhosis[12]. 
Statistical analysis
Histopathologic results were used as a standard 
reference. Generalized estimating equations were 
used to analyze the association between liver fibrosis 
grades and perfusion parameters. The US examination 
parameters measured on the last day and the 
difference between day 0 (before operation) and 
the last day were evaluated. Odds ratios (ORs) with 
95%CI were calculated for all parameters. Statistically 
significant results were assumed when the P value was 
less than 0.05 in all cases. Analysis was performed 
using SAS software (version 9.2; SAS Institute Inc., 
Cary, NC, United States).
RESULTS
From the nine rabbits, the CEUS and laboratory tests 
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Figure 1  Time-intensity curve from contrast enhancement ultrasonography of the liver of a rabbit. The contrast enhancement ultrasonography (CEUS) was 
performed with a high frequency linear transducer and the time-intensity curve was automatically presented as an absolute time to echo mean (dB) curve with a curve 
fitting method. 
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decreased during follow-up. However, total bilirubin 
levels were persistently elevated during follow-up 
(mean: 5.4-5.7 mmol/L). 
Before the CEUS study, intrahepatic bile duct 
dilatation was detected in all rabbits. On CEUS, the 
time-intensity curve was obtained as a typical pattern 
after bolus injection, showing an early and rapid rising 
slope and a gradual decreasing slope after reaching PSI 
(Figure 1). The perfusion analysis results obtained from 
this curve are summarized in Table 2. Among the four 
perfusion parameters, only PSI measured on the last day 
demonstrated a significant association with liver fibrosis 
grades (OR = 1.392, 95%CI: 1.114-1.741, P = 0.004) 
(Figure 2). The difference between the mean value on 
the last day and that of day 0 (before operation) also 
indicated that PSI was associated liver fibrosis (OR = 
1.191, 95%CI: 0.999-1.419, P = 0.051). The other 
parameters including MTT, AUC, and TTP showed no 
significant correlation with liver fibrosis grades. 
DISCUSSION
Liver cirrhosis is characterized by morphologic and 
hemodynamic changes of the general liver. The 
morphologic changes include coarse liver parenchymal 
echogenicity, liver surface nodularity, left lobe 
hypertrophy, enlargement of the hilar periportal space, 
and secondary changes from portal hypertension, 
such as splenomegaly and ascites[13,14]. Hemodynamic 
change is due to global change in liver perfusion 
that results from sequential changes of arterialized 
were performed until postoperative day 7 in two 
rabbits, day 10 in one rabbit, day 14 in three rabbits, 
day 18 in one rabbit, and day 21 in two rabbits. 
Histological grades of liver fibrosis were grade 1 in 
one rabbit, grade 2 and 3 in three rabbits each, and 
grade 4 in two rabbits. The follow-up duration in each 
fibrosis grade was 18 d in fibrosis grade 1, 10-14 d in 
grade 2, 7-14 d in grade 3, and 21 d in grade 4.
The laboratory test results are summarized 
in Table 1. The AST, ALT, and total bilirubin levels 
were within normal range in the initial preoperative 
study and all the values were markedly increased 
on postoperative day 7. The levels of AST and ALT 
Table 1  Laboratory result changes in preoperative and postoperative tests
Preoperative day (day 0)
(n  = 9)
Postoperative day 7
(n  = 9)
Postoperative day 14
(n  = 6)
Postoperative day 21
(n  = 2)
Aspartate aminotransferase (IU/L) 24.6 ± 14.0   94.3 ± 55.1 46.7 ± 16.9 55.5 ± 2.1
Alanine aminotransferase (IU/L) 64.8 ± 28.8 217.8 ± 94.6 49.7 ± 10.2      94 ± 12.7
Total bilirubin (mmol/L) 0.2 ± 0.1   5.4 ± 3.1 5.7 ± 3.5   5.5 ± 1.5
Data are presented as the mean ± SD.
Table 2  Liver fibrosis grades and perfusion parameters 
Fibrosis grades Grade 1 
(n  = 1)
Grade 2 
(n  = 3)
Grade 3 
(n  = 3)
Grade 4 
(n  = 2)
Odds ratio
(95%CI)
P  value1
Mean value on the last day 
   Peak signal  intensity (dB)     10.28   10.53 ± 1.53   12.64 ± 0.29     14.35 ± 0.33 1.392 (1.114-1.741)  0.0042
   Mean transit time (s)     63.27 49.15 ± 6.7   45.40 ± 5.91     45.78 ± 0.97 0.979 (0.946-1.013) 0.215
   Area under the curve (dB s) 1160.84     945.08 ± 196.93 1146.56 ± 39.96 1406.26 ± 3.36 1.001 (1.000-1.003) 0.113
   Time to peak (s)     23.18   20.35 ± 3.26   21.85 ± 3.37     27.33 ± 3.39 1.052 (0.959-1.154) 0.284
Mean value difference on the last day and mean value on day 0
   Peak signal intensity (dB)       1.63 -0.95 ± 1.1     0.15 ± 1.38         5.2 ± 0.84 1.191 (0.999-1.419) 0.051
   Mean transit time (s)       2.78   -4.64 ± 7.67    -14.24 ± 13.21       4.67 ± 0.57 1.001 (0.977-1.026) 0.946
   Area under the curve (dB s)   196.26   -272.71 ± 154.65    -259.65 ± 267.88     631.21 ± 92.03 1.001 (1.000-1.002) 0.160
   Time to peak (s)     1.6    1.76 ± 4.96    -0.12 ± 3.52     10.42 ± 2.13 1.053 (0.969-1.143) 0.222
1From generalized estimating equations; 2Statistically significant results were assumed when the P value was less than 0.05. Data are presented as the 
estimated mean ± SE.
Figure 2  Peak signal intensity and liver fibrosis grade associations. The 
peak signal intensity measured on the last day showed significant association 
with liver fibrosis grades with an OR = 1.392 (95%CI: 1.114-1.741, P = 0.004). 
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capillaries, decreased portal flow and increased arterial 
flow that compensates for the other changes[14-16]. 
Various imaging modalities have been used to evaluate 
liver fibrosis to detect morphologic or hemodynamic 
changes.
Even though liver biopsy is a gold standard for 
diagnosing liver fibrosis, it is limited because of its 
invasive nature and sampling errors[17,18]. Abdominal 
US is commonly performed in clinical practice because 
it can evaluate morphologic and hemodynamic 
changes using grayscale and Doppler studies[13]. 
Previous studies demonstrated that the accuracy for 
detecting liver cirrhosis using US was 82%-88%[14,19]. 
However, this evaluation has limited accuracy for early 
liver fibrosis detection. CT also can be used to evaluate 
liver fibrosis and a recent study demonstrated that 
early fibrotic change could be detected using perfusion 
CT[20]. However, CT is associated with radiation hazards 
and insufficient spatial resolution in small infants, 
and is not advantageous because it uses iodinated 
contrast agents[14]. MRI can also be used to evaluate 
liver fibrosis and is better than CT. However, MRI is 
limited because of the non-linear relationship between 
tracer concentration and acquired signal intensity[14]. 
Additionally the cost, need for sedation, and longer 
examination time are also important drawbacks of 
MRI in pediatric patients[13]. A Fibroscan showed good 
correlation with liver fibrosis detection[17]; however, 
this method lacks anatomical information. The 
acoustic radiation force impulse imaging and shear 
wave elastography allow liver fibrosis assessment, but 
standard cutoff values between normal and pathologic 
conditions have not yet been identified and the 
recent report demonstrated that the obtained values 
differed according to the frequency of transducers and 
acquisition depths[21]. Therefore, CEUS can be applied 
as an optimal tool to assess liver fibrosis because it 
includes grayscale images from US and even subtle 
perfusion changes can be quantitatively detected from 
contrast administration, without radiation exposure or 
need for sedation in infants. 
Several clinical studies used CEUS for adults 
with chronic viral liver disease[15,22-26]. Ridolfi et al[22] 
showed that PSI was higher in cirrhosis patients, as in 
our study, and TTP and MTT were shorter in cirrhotic 
patients compared with the control group. In the other 
previous studies, liver transit time was widely used for 
assessing liver fibrosis and cirrhosis[15,23,24,26]. The liver 
transit time was significantly shortened in advanced 
liver fibrosis by arteriovenous shunting and arterialized 
capillaries[14,16,26]. 
Two CEUS studies that assessed liver fibrosis 
evaluation were performed in an animal model and 
had different results[6,27]. In these studies, liver fibrosis 
was induced by administering carbon tetrachloride 
(CCl4) via intraperitoneal routes. Zhang et al[27] applied 
CEUS in rabbits and showed that PSI was decreased 
with the development of liver fibrosis, which was 
contrary to our results. In their study, hepatic artery 
to vein transmission time was significantly shorter 
in the advanced fibrosis group than the other groups. 
They suggested that decreased PSI resulted from 
decreased sinusoid volume caused by fibrosis and 
explained that decreased transit time through the liver 
resulted from increased intrahepatic shunts, similar to 
the explanation given in a human study. Ying et al[6] 
used CEUS in rats and also demonstrated that PSI was 
significantly decreased. However, TTP was significantly 
increased in the advanced fibrosis group compared with 
the early fibrosis group. They explained that delayed 
TTP was obtained from decreased hepatic sinusoidal 
volume derived from fibrotic change, which could lead 
to reduced liver blood flow velocity, overall decreased 
portal vein volume, and a longer perfusion time for liver 
parenchyma.   
In the literature reviewed, PSI and TTP showed 
different results for evaluating advanced liver fibrosis. 
The two main explanations for hepatic perfusion 
change were decreased sinusoidal volume by fibrotic 
change and increased intrahepatic shunt flow causing a 
considerable amount of blood bypass. However, these 
pathogeneses could vary in our study. Chronic viral 
hepatitis in adults and intraperitoneal CCl4 injection in 
animals are different conditions compared with the bile 
duct ligation used in our study. The former conditions 
mainly induce hepatotoxicity, while bile duct ligation 
can cause cholestasis, recurrent cholangitis, and biliary 
cirrhosis. Previous animal studies revealed that liver 
fibrosis from hepatitis resulted from the activated 
hepatic stellate cells and portal myofibroblasts which 
lead to progressive portal fibrosis, periportal fibrosis 
and development of regenerative nodules[6,27,28]. 
However, liver fibrosis from obstructive cholestasis 
is different from this pattern. Obstructive cholestasis 
leads to bile duct proliferation and hyperplasia of bile 
duct epithelium which aggravates the generation of 
profibrogenic cytokine transforming growth factor b to 
form a scar[29,30]. Moreover, we used rabbits that had 
body weights of 3-4 kg, which was similar to full-term 
neonates, to evaluate liver fibrosis from biliary atresia. 
Using rats as an animal model has limitations because 
of their small liver volume. This is because it is more 
complicated to avoid small liver vessels for quantitative 
CEUS analysis.   
In our study, laboratory tests showed that AST and 
ALT levels were markedly increased on postoperative 
day 7 and decreased during follow-up. However, these 
levels did not reach the normal range. Even though 
inflammatory changes from bile duct obstruction de-
creased gradually during the follow-up, it persisted 
in addition to liver fibrosis. This is similar to clinical 
conditions in biliary atresia. In children with biliary 
atresia, the intrahepatic inflammatory processes 
can continue for at least six months after Kasai 
portoenterostomy, which might cause progressive 
fibrosis and cirrhosis[10,31]. Moreover, the progression of 
Shin HJ et al . Contrast-enhanced ultrasonography for liver fibrosis
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fibrosis is more likely when cholangitis is recurrent[32]. 
Lee et al[29] demonstrated that biliary atresia was 
characterized by portal tract inflammation and biliary 
cirrhosis could develop in late stages. They showed 
that patients with biliary atresia had significantly 
larger hepatic artery, representing hypertrophic and 
hyperplastic changes that resulted from liver fibrosis. 
A recent review of hepatic fibrosis and cirrhosis 
explained that before an overall decrease in hepatic 
perfusion as a late change, hepatic arterial flow 
increases as a compensatory response resulting from 
arterialization of capillaries and reduced portal venous 
flow[14]. The increased PSI in our study could result 
from the increased compensatory hepatic arterial flow 
that occurs before advanced liver cirrhosis. However, 
we could not evaluate the diameter or Doppler flow 
pattern of the hepatic artery from rabbits due to small 
size and large variation of rabbit hepatic arteries 
detected during the operation. Moreover, bile duct 
ligation does not have the same pathophysiology as 
biliary atresia. Further studies are needed to validate 
the utility of perfusion analysis using CEUS to evaluate 
liver fibrosis in children with biliary atresia. 
Our study had several limitations. First, the number 
of subjects was small. Only one rabbit was included 
in fibrosis grade 1. This could lower the statistical 
power of our study and could be a key reason why 
other parameters, including MTT, AUC and TTP, were 
not significantly correlated with fibrosis grade, in 
contrast to other studies[6,13,22,25]. However, our study 
demonstrated the feasibility of CEUS to evaluate 
liver fibrosis from biliary obstruction using an animal 
model. Though the contrast agent for CEUS has not 
been approved yet for pediatric patients, this study 
demonstrated the usefulness of CEUS for assessing 
liver fibrosis in children with biliary atresia. Second, we 
did not evaluate intra- and inter-observer variability 
while performing CEUS and achieving perfusion values 
from ROI. However, we tried to reduce variability by 
evaluating CEUS in the most homogeneous hepatic 
parenchyma for 3 min with two contrast injections. 
The values from the ROI were obtained three times 
to reduce intra-observer variability. Third, different 
pharmacokinetics, according to the contrast agent, 
could affect the results of perfusion parameters[14]. 
Moreover, a post-processing procedure is required to 
obtain perfusion parameters using different software 
without standardization. Therefore, additional studies 
with a large sample size and including patients with 
biliary atresia are necessary to establish the potential 
of CEUS for evaluating liver fibrosis from biliary 
obstruction. 
In conclusion, this animal study demonstrates that 
CEUS can be used to evaluate liver fibrosis from biliary 
obstruction using PSI. Further studies are needed to 
validate the clinical utility of CEUS in the evaluation of 
liver fibrosis in children with biliary atresia.
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COMMENTS
Background
Contrast-enhanced ultrasonography (CEUS) is an examination based on blood 
pool tracer visualization using ultrasound contrast agents during real-time 
ultrasonography (US) imaging. CEUS was proposed for the evaluation of liver 
fibrosis and previous studies demonstrated the role of CEUS for evaluating liver 
fibrosis for detecting local and hemodynamic changes accompanied by fibrotic 
liver changes. However, no previous studies have evaluated the utility of CEUS 
for liver fibrosis caused by biliary obstruction, which can be the major cause of 
liver fibrosis in children.
Research frontiers
Liver cirrhosis is characterized by morphologic and hemodynamic changes 
of the general liver. Hemodynamic change is due to global change in liver 
perfusion that results from sequential changes of arterialized capillaries, 
decreased portal flow and increased arterial flow that compensates for the 
other changes. To assess liver fibrosis, the current research hotspot is the 
utilization of CEUS in this area because it includes grayscale images from US 
and even subtle perfusion changes can be quantitatively detected from contrast 
administration, without radiation exposure or need for sedation in infants. 
Innovations and breakthroughs
Two previous CEUS studies performed liver fibrosis evaluation in an animal 
model and had different results. In these studies, liver fibrosis was induced 
by administering carbon tetrachloride via intraperitoneal routes to make 
hepatotoxicity. However, to make a liver fibrosis model specifically induced 
by obstructive cholestasis, we performed bile duct ligation in rabbits that had 
body weights of 3-4 kg, which was similar to full-term neonates, to evaluate 
liver fibrosis from biliary atresia. We performed liver CEUS in preoperative 
and postoperative days sequentially and obtained perfusion parameters 
quantitatively. The parameters were compared with final histopathologic fibrosis 
grade according to the Metavir score system immediately after sacrifice.
Applications
The study results suggest that the peak signal intensity measured on the last 
day demonstrated a significant association with liver fibrosis grades and the 
difference in peak signal intensity between the day before the operation and the 
last day also showed an association with liver fibrosis. It implies that CEUS can 
be useful to evaluate liver fibrosis induced from biliary obstruction using peak 
signal intensity as a parameter.
Terminology
CEUS is a new examination method using real time US to visualize the 
administered ultrasound contrast agent which travels the blood stream in the 
form of microbubbles. Therefore, CEUS can quantitatively measure blood flow 
and perfusion changes using contrast kinetic curves derived from quantification 
software.
Peer-review
This is an interesting research study which evaluated the utility of recently 
developed CEUS to demonstrate the relationship between perfusion 
parameters and liver fibrosis grades. This study also correlated the histological 
fibrosis grades with vascular change of the liver using an animal model focused 
on liver fibrosis from bile duct obstruction.
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